sb 203580 has been researched along with metoprolol in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (metoprolol) | Trials (metoprolol) | Recent Studies (post-2010) (metoprolol) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 5,821 | 1,743 | 1,304 |
| Protein | Taxonomy | sb 203580 (IC50) | metoprolol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 2.573 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.176 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 4.87 | |
| Cytochrome P450 2J2 | Homo sapiens (human) | 4.87 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Du, Y; Han, X; Li, X; Liu, H; Song, K; Wang, J; Yan, L; Zhan, W | 1 |
1 other study(ies) available for sb 203580 and metoprolol
| Article | Year |
|---|---|
β1-Adrenoceptor autoantibodies from DCM patients enhance the proliferation of T lymphocytes through the β1-AR/cAMP/PKA and p38 MAPK pathways.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Agonists; Aged; Animals; Autoantibodies; Cardiomyopathy, Dilated; Cell Proliferation; Cyclic AMP-Dependent Protein Kinases; Female; Humans; Imidazoles; Interferon-gamma; Isoproterenol; Isoquinolines; Male; Metoprolol; Middle Aged; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-1; Signal Transduction; Sulfonamides; T-Lymphocytes | 2012 |